Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02950077
Other study ID # 2000020043
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date April 14, 2017
Est. completion date April 14, 2020

Study information

Verified date June 2020
Source Yale University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study is a 'pilot study' to assess the effect of a mindfulness-based stress reduction (MBSR) intervention on patients with autoimmune liver disease specifically autoimmune hepatitis type I. MBSR is a standardized intervention that has shown benefit in addiction disorders and other psychiatric disorders. There has been no study evaluating or showing the benefit of the use of MBSR in autoimmune liver disease. With published data showing the evidence of an association of stress and relapse in autoimmune hepatitis, it is hypothesized that such an intervention such as MBSR may have therapeutic effect in patients with autoimmune liver disease.


Description:

With the understanding that autoimmune hepatitis has a relationship with psychological stress, the use of a strategy such as mindfulness stress based reduction (MBSR) may similarly have a substantial impact as seen in other disease conditions. The proposed hypothesis is that undergoing MBSR has potential to benefit patients with autoimmune hepatitis in relation to decreased relapse rate and ultimately improved quality of life.

The focus of this study is surrounding the possibility of psychosocial stress for relapse in AIH. The investigators, however, would like to also understand the role of serological testing at the time of these relapses and during states of psychosocial stress to demonstrate if the association can be found. During active disease activity or relapses of autoimmune hepatitis, there is an expected rise in alanine aminotransferase (ALT) and immunoglobulin G (IgG) levels. Demonstrating the correlation of ALT and IgG with disease status and possible improvement with stress modifications is also key for this proposed study.


Recruitment information / eligibility

Status Completed
Enrollment 21
Est. completion date April 14, 2020
Est. primary completion date April 14, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria:

- Between ages 18-80 years

- Diagnosis of Autoimmune Hepatitis Type I

Exclusion Criteria:

Medical

- Hospitalization in the last 30 days

- New immunosuppression agent started <6 weeks prior to study

- Patients with concurrent viral hepatitis and/or alcoholic liver disease

- Patients with decompensated cirrhosis (defined as ascites, encephalopathy, variceal hemorrhage)

- Patients with hepatocellular carcinoma

- Patients post-liver transplantation Psychological

- Any psychotic disorder or current psychiatric symptoms

Attitudinal

- Inability to commit to program schedule and attendance of classes

Physical

- Inability to physically attend classes; disability or physical impairment not included as an exclusion criteria Other

- Inadequate English proficiency

- Inability to read and/or write

Study Design


Intervention

Behavioral:
mindfulness based stress reduction
The intervention will be delivered in a group setting and the group will meet for 2 hours once per week for 8 weeks. The intervention is based on new neuroscience of stress and resilient adaptive behaviors, mindfulness based stress reduction, therapeutic breath and synchronized yogic movement with a focus on the lower abdomen, integrated with cognitive and behavioral strategies for self-control and healthy decision making.

Locations

Country Name City State
United States Yale Liver Center New Haven Connecticut

Sponsors (1)

Lead Sponsor Collaborator
Yale University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Subjective Stress: The Perceived Stress Scale Subjective Stress: The Perceived Stress Scale, a 14-item self-report scale that assesses the degree to which individuals appraise situations in their lives as stressful, will be used to assess subjective interpretation of stress and assign subjects to the low stress or high stress condition. Scale It has excellent test-retest reliability and good construct validity and has been used with adults and adolescents.
Scale ranges from 0 to 40. A higher score indicates higher stress.
12 months
Primary Change in Recent Life Stress: Life Experience Survey The LES is a widely used 57 item self-report measure. It shows convergent validity with personality measures (e.g., anxiety) and is not correlated with social desirability measures.
Scale ranges from -250 to +250. A higher score indicates higher stress.
12 months
Primary Daily Hassles Questionnaire This self-report item measures how stressful subjects perceived situations occurring in the past year of their life.
Scale ranges from 0 to 351. A higher score indicates higher stress.
12 months
Primary The Brief Self-Control Scale The Brief Self-Control Scale will be used to measure self-reported self-control and impulsivity. The BSCS also shows good internal consistency (alphas = .83 - .84) and high retest reliability (.87).
Scale ranges from 13-65. A higher score indicates better self-control.
12 months
Secondary Change in ALT levels and IgG levels Abnormal AST and ALT will be defined as >2x upper limits of normal
Normal Lab ranges that will be used are the following:
AST (0 - 34 U/L)
ALT (0 - 34 U/L)
IgG (355 - 1887 mg/dL)
These levels are used together for clinical significance and diagnosis.
12 months
Secondary Change in average medication needed E.g (changes in monthly prednisone dose) 12 months
Secondary Change in number of relapses Relapse is defined in one of two ways once immunosuppression has been tapered off:
I. An increase in the AST or ALT =2 X ULN (upper limit of normal) II. An increase in AST and/or ALT = 2 X the prior level of AST or ALT on routine labs checked at start of clinical study
up to 2 years
Secondary Demonstration of MIF and CD74 have a role as a biomarker for disease activity Demonstration of a correlation of serum MIF and CD74 levels with autoimmune hepatitis disease activity. 12 months
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06020976 - Pattern of Autoimmune Hepatitis in Children In Sohag University Hospital
Recruiting NCT05476900 - A Study to Evaluate the Efficacy and Safety of HR19042 Capsules in the Treatment of Autoimmune Hepatitis. Phase 2
Recruiting NCT05635266 - Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
Recruiting NCT06250309 - Mediterranean Diet Versus Western Diet on Fatigue in Autoimmune Hepatitis Patients N/A
Recruiting NCT01661842 - Umbilical Cord Mesenchymal Stem Cells for Patients With Autoimmune Hepatitis Phase 1/Phase 2
Terminated NCT04339621 - AIH Risk Stratification With Multiparametric MRI
Not yet recruiting NCT04371718 - Effect of JKB-122 on Prednisolone and Azathioprine Induced Remission in Autoimmune Hepatitis (AIH) Phase 2
Completed NCT02239562 - sPIF CLINICAL STUDY PROTOCOL IN AUTOIMMUNE HEPATITIS Phase 1
Recruiting NCT05569759 - A Study of Zetomipzomib (KZR-616) in Patients With Autoimmune Hepatitis (PORTOLA) Phase 2
Completed NCT02463331 - Association of Chloroquine and Prednisone as an Alternative Treatment for Autoimmune Hepatitis Phase 4
Not yet recruiting NCT06356506 - A Study on Factors of Biochemical Response in Autoimmune Hepatitis
Terminated NCT04203875 - Abatacept for Treatment of Recurrent or de Novo Autoimmune Hepatitis Phase 1
Recruiting NCT06078098 - Development of a Autoimmune Hepatitis Patient's Database Linked to a Biological Sample Storage
Completed NCT00838214 - Budesonide 3x3mg/d Versus Prednisone in Active Autoimmune Hepatitis Phase 2/Phase 3
Recruiting NCT05810480 - PredIcting sterOid depeNdEnt livEr injuRy With Polyreactive Immunoglobulin G
Recruiting NCT03743272 - Repeatability and Reproducibility of Multiparametric MRI
Completed NCT03979053 - Quantitative Magnetic Resonance Imaging to Aid Clinical Decision Making in Autoimmune Hepatitis.
Not yet recruiting NCT04902807 - Conception of a Diagnosis, Prognosis and Therapeutic Decision Tool for Patients With Autoimmunity and Inflammation
Recruiting NCT04933292 - A Randomised Clinical Trial Assessing the Efficacy and Safety of Mycophenolate Mofetil Versus Azathioprine for Induction of Remission in Treatment Primary Biliary Cholangitis-Autoimmune Hepatitis Overlap Syndrome Phase 4
Not yet recruiting NCT06455280 - SIPLIZUMAB in AILD and LT Phase 1